While, anti-VEGF agents may be beneficial for the management of NVG reducing the need for glaucoma surgery and decreasing complications in eyes with neovascular glaucoma, the addition of intravitreal bevacizumab did not seem to increase the success rate in previous studies [24, 25]. Here, VEGFA is linked to neovascular glaucoma.